Comprehensive Overview on Celsius Holdings' Market Position
Morgan Stanley Maintains Equalweight Rating on Celsius Holdings
Morgan Stanley has reaffirmed its Equalweight rating for Celsius Holdings (NASDAQ: CELH), establishing a price target of $50.00. The firm's observations indicate a modest increase in sales, with a year-over-year sales growth of 5% noted in the two weeks ending October 5, 2024, across the Nielsen xAOC+C channels. While this growth may seem limited, it reflects a slight improvement in the average sales growth over the past two years.
According to recent data, Celsius's market share, excluding powdered products, has experienced a decline of 20 basis points sequentially to settle at 9.5%. This marks a decrease from the higher market share of 10.7% noted earlier in May. However, the total distribution points (TDP) for Celsius have remained stable with mid-30% growth, while the velocity of sales has shown a minor sequential improvement, even though it still reflects a year-over-year decline of low-20%.
Another notable trend is the sequential decrease in Celsius's promotional sales percentage, although it has increased when compared to last year. Additionally, the price/mix ratio has decreased by 3% in the last two weeks, an improvement over the 5% drop observed in the previous two weeks. Moreover, the sales metrics from Nielsen's new Full View Measurement dataset, incorporating 1P sales estimates from Amazon, suggest that Celsius's sales performance is on par with other channels, despite a lower implied share on Amazon compared to alternative sources.
Financial Forecasts and Market Insights
Morgan Stanley previously adjusted its projections for Celsius, downgrading third-quarter and full-year forecasts on September 4. The adjustments were attributed to PepsiCo's inventory reductions and overall softness in the beverage category, with an additional downgrade occurring on September 23 due to promotional accounting impacts linked to PepsiCo's inventory actions. The firm has emphasized the absence of a clear catalyst for Celsius until scanner data trends show positive movement.
Celsius Holdings recently disclosed a remarkable 23% rise in total revenue, achieving a record high of $402 million. International revenue reported a notable 30% increase to $19.6 million. However, the anticipated inventory reductions from PepsiCo are expected to have a significant impact on both sales and EBITDA for the upcoming third quarter and the full year of 2024. In light of these developments, various financial institutions, such as Piper Sandler, Jefferies, and Roth/MKM, have revised their price targets for Celsius Holdings, acknowledging the updated financial outlook. Piper Sandler has maintained its Overweight rating, reducing its price target from $50 to $47, while Jefferies and Roth/MKM set their targets at $48 and $43 respectively.
Strategic Board Changes and Growth Projections
Stifel financial services maintains a positive outlook for Celsius Holdings, indicating expectations for enhanced sales within convenience stores by 2025. This optimistic perspective coincides with recent significant changes within the company’s board, highlighted by the appointment of Hans Melotte—an experienced professional from Starbucks and Johnson & Johnson—who joins the board following Jim Lee's resignation.
Insights on Revenue Growth and Stock Performance
Recent InvestingPro insights underscore the context of Morgan Stanley's analysis concerning Celsius Holdings (NASDAQ: CELH). Despite noted slower growth, Celsius achieved impressive revenue growth of 56.5% over the last year, reaching a total of $1.49 billion. This robust financial performance is exhibited through a gross profit margin of 50.45% and an operating income margin of 22.42% during the same timeframe.
However, it is essential for investors to acknowledge that CELH's stock price has undergone notable volatility, with a decline of 33.84% over the past three months and a significant 52.62% drop over the last six months. This trend appears to resonate with Morgan Stanley's cautious viewpoint regarding the stock's near-term future.
Notably, Celsius is currently trading at a low P/E ratio in comparison to its expected earnings growth, highlighted by a PEG ratio of 0.13, which might suggest potential undervaluation given recent market challenges. Financially, the company is situated well, as it holds a greater amount of cash than debt on its balance sheet, indicating solid financial stability amid current uncertainties in the market.
Frequently Asked Questions
What is Morgan Stanley's rating for Celsius Holdings?
Morgan Stanley has maintained an Equalweight rating for Celsius Holdings with a price target of $50.00.
How did Celsius Holdings perform in terms of revenue?
Celsius Holdings reported a 23% increase in total revenue, reaching a record $402 million.
What challenges is Celsius facing regarding market share?
Celsius's market share, excluding powders, has declined to 9.5%, down from 10.7% earlier this year.
Are there any recent changes in Celsius's board of directors?
Yes, Hans Melotte from Starbucks and Johnson & Johnson recently joined the board after Jim Lee's resignation.
What financial outlook do analysts have for Celsius Holdings?
Several financial firms have revised their price targets for Celsius, with Piper Sandler reducing its target from $50 to $47 amid projected impacts from PepsiCo's inventory actions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Bitcoin's Rally Potential: Factors to Watch Before the Election
- Kestra Holdings Partners with Stone Point Capital for Growth
- Anthony Pompliano Shares Insights on Tesla's Influence on Stablecoins
- Church Pension Group Welcomes Rev. Arlette Benoit Joseph as CCRO
- Amazon Teams Up with Databricks to Revolutionize AI Cost Savings
- LeChase Construction Elevates Leadership for Future Growth
- Dell Technologies Rolls Out New Innovations Amid Stock Changes
- Avalanche Price Dips: Insights on Recent Market Trends
- Kraken Empowers Users with Ethereum Restaking Convenience
- Analyzing Palantir Technologies: Insights and Comparisons
Recent Articles
- CVR Partners Plans to Unveil Third Quarter Financials Soon
- Alto Ingredients Reports Exciting Developments in Production
- Needham Adjusts ViaSat Stock Target Amid Competition and Supply Issues
- Yoshiharu Global Partners with Chengdu Octaday for Growth
- BMO Adjusts Constellation Brands Target Price, Maintains Rating
- Banzai Partners with MZ Group to Enhance Investor Relations
- Expion360 Gears Up for LD Micro Main Event with New Insights
- Apple's Ambitious Car Project Ends Amidst Competition Shifts
- UnitedHealth Group's Q3 Performance: Insights and Analysis
- Citigroup Faces Challenges as Profit Declines in Recent Quarter
- Progressive Insurance Reports Impressive Q3 2024 Financials
- Statkraft AS Advances Sustainability with New Green Bonds
- Ciena Corp's Future Looks Bright Despite Recent Downgrade
- Investigation Looms Over ADMA Biologics Amid Auditor Departure
- Progressive Beats Earnings Estimates with Strong Revenue Growth
- Serious Concerns for Acadia Healthcare Following Stock Plummet
- Coeptis Therapeutics to Showcase Innovations at Key Conferences
- DT Midstream to Reveal Q3 Financial Outcomes and Call Schedule
- Investors Rally Around Serra Ventures' Ag & Food Tech Fund II
- Lucid Diagnostics Achieves Key Patent Milestone for Cancer Test
- CareDx and JD.com: Pre-Market Declines Raise Investor Concerns
- Discover SuperStix™: The New Organic Hydration Revolution
- Tyfone Introduces Payfinia Inc. to Transform Payment Solutions
- Galileo Emerges as a Leader in AI Evaluation with New Funding
- Expert Analysts Review High Yield Dividend Stocks Today
- UBS Continues Positive Outlook for Freeport-McMoRan Amid Setbacks
- Exciting Opportunities for Teams in the Future City Challenge
- Rockefeller Asset Management Launches RSMC for SMID Cap Investors
- Jim Cramer Champions Uranium Energy Corp: A Look at Stocks
- Fonoa Enhances Indirect Tax Compliance Solutions with PwC Deal
- MDVIP Enhances Patient Care with New Practices in NC
- Innovation Beverage Group Sets Sights on Global Horizons in Beverages
- EBANX Prepares for Pix Automático Launch: A Game Changer
- Oppenheimer Maintains Perform Rating on AMD as AI Growth Surges
- Goldman Sachs Announces Impressive Q3 Earnings Growth Surge
- Johnson & Johnson's Strong Q3 Performance Boosts Outlook
- EarthDaily Analytics Expands with Descartes Labs Acquisition
- Amgen's UPLIZNA Shows Great Promise for Myasthenia Gravis
- Transforming Enterprises with DRUID AI's New Conductor Solution
- Progressive Corporation Reports Strong Performance in Q3 2024
- Empowering Businesses with Autonomous AI: DRUID Conductor Launch
- Twist Bioscience Welcomes Mike Fero as New Chief Information Officer
- Smithers Attains C3PAO Designation to Boost Cybersecurity Trust
- Junee Limited's Strategic Steps Towards AI Infrastructure Growth
- Johnson & Johnson's Nipocalimab Trial Marks a Major Milestone
- Second Avenue Capital Partners Secures $120M Credit for Acquisition
- Petra Automotive Products Partners with Meineke for Growth
- Ventyx Shares Encouraging Phase 2 Data for Tamuzimod in UC
- Integracare Inc. Broadens Its Presence in Ontario Market
- Glenn Llopis Unveils Essential Leadership Guide for Healthcare Executives